Opus Genetics (IRD) Revenue (2010 - 2026)

Opus Genetics (IRD) has reported Revenue for 8 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue fell 50.64% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $12.0 million (down 12.22% YoY), while the FY2025 annual figure was $14.2 million, up 29.15% from the prior year.
• Revenue eased to $2.2 million in Q1 2026 per IRD's latest filing, from $3.9 million in the prior quarter.
• Across five years, Revenue topped out at $39.8 million in Q4 2022 and bottomed at $1.1 million in Q2 2024.
• Historically, Revenue has averaged $6.2 million across 5 years, with a median of $3.4 million in 2023.
• Annual changes were most pronounced in 2023 — Revenue sank 95.76% — and 2025, when it soared 159.17%.
• Opus Genetics' Revenue stood at $39.8 million in 2022, then tumbled by 95.76% to $1.7 million in 2023, then soared by 154.41% to $4.3 million in 2024, then retreated by 10.16% to $3.9 million in 2025, then plunged by 44.19% to $2.2 million in 2026.
• Business Quant data shows IRD's Revenue at $2.2 million in Q1 2026, $3.9 million in Q4 2025, and $3.1 million in Q3 2025.